title: Freeze-fracture study of plasma membranes in wild type and daunorubicin-resistant Ehrlich ascites tumor and P388 leukemia cells.
abstract: The plasma membrane is considered to play a major role in the development and maintenance of the multidrug resistance (MDR) phenotype, a role which may in part be mediated by an inducible 170 kD transmembrane protein (P-170). The present freeze-fracture study of plasma membranes of daunorubicin-resistant Ehrlich ascites and P388 leukemia cells demonstrated a significant increase in the density of intramembrane particles (IMP) in the P-face, but not the E-face, of resistant sublines compared with wild type cells. Furthermore, a three-dimensional histogram plot of the diameters of P-face IMPs in Ehrlich ascites tumor cells showed the emergence of a subpopulation of 9 X 11 nm IMPs not found in wild type cells. The size of these IMPs would be consistent with a MW of approximately 340 kD, thus indicating that P-170, shown to be present in both resistant cell lines by Western blot analysis and immunohistochemical staining, exists as a dimer in the plasma membrane. Incubation with the calcium channel blocker verapamil, in concentrations known to inhibit daunorubicin efflux in resistant cells, showed evidence of membrane disturbance in the form of IMP clustering in both wild type and resistant Ehrlich ascites tumor cells. However, incubation with daunorubicin itself did not alter the freeze-fracture morphology of the plasma membranes.
authors.affiliation: Department of Pathology, Herlev University Hospital, Denmark.
authors.forename: M
authors.initials: M
authors.lastname: Sehested
authors.forename: D
authors.initials: D
authors.lastname: Simpson
authors.forename: T
authors.initials: T
authors.lastname: Skovsgaard
authors.forename: P
authors.initials: P
authors.lastname: Buhl-Jensen
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal; D015153:Blotting, Western; D002286:Carcinoma, Ehrlich Tumor / Q000473:pathology*; D002462:Cell Membrane / Q000473:pathology; D003630:Daunorubicin / Q000494:pharmacology*; D004351:Drug Resistance; D005614:Freeze Fracturing; D007941:Leukemia P388 / Q000473:pathology*; D007942:Leukemia, Experimental / Q000473:pathology*; D010641:Phenotype; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000473:pathology
chemical_list: D000911:Antibodies, Monoclonal; D003630:Daunorubicin